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Abstract 
Background: Our aim was to identify and compare modifiable risk factors associated with 
adverse pregnancy outcomes in women with type 1 and type 2 diabetes and to identify effective 
maternity clinics. 
Methods: We included 17,375 pregnancies in 15,290 women with diabetes in a population-
based cohort study across 172 maternity clinics in England, Wales and the Isle of Man. 
Obstetric complications (preterm delivery, large birthweight) and adverse pregnancy outcomes 
(congenital anomaly, stillbirth, neonatal death) were obtained for pregnancies completed 
between 01 January 2014 and 31 December 2018. We assessed associations between 
modifiable (glycaemia, obesity, clinic) and non-modifiable risk factors (age, deprivation, 
ethnicity) with pregnancy outcomes. 
Results: Of 17,375 pregnancies, 8,690 (50.0%) were in women with type 1 and 8,685 (50.0%) 
in women with type 2 diabetes. The rates of preterm delivery (42.5% type 1, 23.4% type 2), 
and large birthweight (52.2% type 1, 26.2% type 2) were higher in type 1 diabetes (p<0.001). 
The prevalence of congenital anomaly (44.8/1000 type 1, 40.5/1000 type 2; p=0.175), and 
stillbirth (10.4/1000 type 1, 13.5/1000 type 2; p=0.072) did not differ but neonatal death rates 
(7.4/1000 type 1, 11.2/1000 type 2; p=0.013) were higher in type 2 diabetes. Independent risk 
factors for perinatal death were third trimester HbA1c > 48mmol/mol (OR 3.06, 95% CI 2.16 
to 4.33), living in the highest deprivation quintile (OR 2.29 95% CI 1.16 to 4.52) and having 
type 2 diabetes (OR 1.65 95% CI 1.18 to 2.31). Variations in glycaemia and large birthweight 
were associated with maternal characteristics (diabetes duration, deprivation, BMI) without 
substantial differences between clinics.  
Interpretation: Our data highlight persistent adverse pregnancy outcomes in type 1 and type 
2 diabetes. Maternal glycaemia and obesity are the key modifiable risk factors. No clinics were 
achieving appreciably better outcomes, suggesting that healthcare system changes are needed 
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across all clinics.  
Introduction 
As the prevalence of diabetes continues to rise, pregnancies complicated by maternal diabetes 
are becoming an increasing concern. The incidence of both gestational diabetes and pregnancy 
complicated by type 1 or type 2 diabetes has doubled, affecting almost one in ten pregnant 
women by 30 years of age (1). Increases of 33-44% in pregnancies complicated by type 1 
diabetes and of 90-111% in pregnancies complicated by type 2 diabetes are reported in 
Northern Europe (2, 3). Pregnancies complicated by pre-existing diabetes are associated with 
preterm delivery and birthweight extremes as well as increased rates of congenital anomaly, 
stillbirth, and neonatal death (4-6).  
Previous studies have documented the pregnancy outcomes associated with type 1 and type 2 
diabetes (1, 2, 4-9). Pregnant women with type 1 diabetes have higher glucose levels than those 
with type 2 diabetes, and higher associated rates of preterm births and large birthweight babies, 
most likely attributable both to glycaemia and body mass index (BMI) (7). Pregnant women 
with type 2 diabetes are older, with higher rates of obesity, ethnic diversity, and deprivation 
compared to women with type 1 diabetes, but they also have lower glucose levels, fewer 
preterm births, and fewer large birthweight babies (10). Nonetheless, adverse pregnancy 
outcomes (congenital anomaly, stillbirth, neonatal death) occur at least equivalently, in women 
with type 1 and type 2 diabetes (2, 6, 11).  
The different contributions of risk factors to obstetric complications and adverse pregnancy 
outcomes in women with type 1 and type 2 diabetes are unclear. It is also unknown whether 
some maternity clinics more successfully achieve antenatal glucose targets and optimal 
pregnancy outcomes, independent of confounding variables (10). Here we report the first five 
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years of data from the National Pregnancy in Diabetes (NPID) audit, encompassing over 
17,000 pregnancies in women with diabetes. Our aim was to identify and compare modifiable 
risk factors associated with type 1 and type 2 diabetes pregnancy outcomes in a large national 
cohort and to identify particularly effective maternity clinics. 
Methods 
Data sources 
All National Health Service (NHS) maternity units in England, Wales and the Isle of Man 
providing antenatal diabetes care are expected to participate in the annual NPID audit 
(http://digital.nhs.uk/npid). Healthcare professionals at each maternity clinic completed web-
based manual data entry forms (which introduces a risk of data entry error) for all pregnant 
women with pre-existing diabetes (ESM 1). Remaining data items were collected by data 
linkage with other systems (Hospital Episodes Statistics data, Patient Episode Database for 
Wales, Core National Diabetes Audit).  
 
The information leaflet and consent forms used met the Health Research Authority 
requirements for clinical audit and research ethics approval was not required. The requirement 
for individual women to provide written informed consent was removed in England from 2018, 
because the legal basis for the National Diabetes Audit data collection and linkage in England 
became a Direction from NHS England to NHS Digital according to section 254 of the Health 
and Social Care Act (HSCA) for England 2012. Individual written consent is still required in 
Wales.  
 
Patient and Public Involvement 
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Patients and the public were involved in the design and conduct of the audit, development and 
agreement of the statistical analyses plan and interpretation and dissemination of results. 
 
Study population, observation period and outcomes 
Our study population included women with pre-existing type 1 and type 2 diabetes who 
completed a pregnancy between 1st January, 2014, and 31st December, 2018. We defined pre-
existing diabetes as diabetes clinically diagnosed before pregnancy and excluded women with 
monogenic diabetes and those who presented with diabetes first recognised during pregnancy. 
We defined gestational age according to the estimated date of delivery based on ultrasound 
assessment at 12 weeks gestation. We categorised births before 37 weeks gestation as preterm. 
Birthweight was adjusted for maternal BMI, ethnicity, neonatal sex and gestational age for 
singleton pregnancies using customised centiles with large and small for gestational age (LGA, 
SGA) defined as birthweight centile >90th and <10th centile respectively (Gestation Related 
Optimal Weight (GROW) centile tool v8 0.4 (UK) 2019 Gestation Network)(12).  
 
Major and minor congenital anomalies were based on the ICD10 codes identified prior to 
hospital discharge. We calculated the congenital anomaly rate as the number of offspring with 
one or more anomalies divided by the number of livebirths, terminations, fetal losses after 20 
weeks. We defined stillbirth as fetal loss occurring after 24 weeks gestation, and neonatal death 
as death of a liveborn infant up to 28 days after delivery. 
 
Definitions of exposures 
Maternal age was grouped as 15-24 years, 25-34 years, 35-44 years and age >45 years. Self-
reported ethnicity was classified as White, Mixed, Asian, Black, Unknown, Other or not 
available (N/A). Social deprivation was based on an index of multiple deprivation score for 
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women whose postcode details were recorded in the National Diabetes Audit (13). Diabetes 
duration was categorised as <1 year, 1-4 years, 5-9 years, 10-14 years and >15 years. Maternal 
body mass index (BMI) was based on the first recorded weight in pregnancy and grouped as 
<18.5 kg/m2, 18.6-24.9 kg/m2, 25-29.9 kg/m2, 30-34.9 kg/m2, 35-39.9 kg/m2, and >40 kg/m2. 
Antenatal glucose measurements were obtained from the first and last glycated haemoglobin 
(HbA1c) values recorded during pregnancy. HbA1c was measured in routine care settings using 
IFCC standard assays. Target glycaemic attainment was defined as HbA1c <48mmol/mol 
(6.5%), in accordance with National Institute for Health and Clinical Excellence (NICE) 
guidelines (14). We considered 5mg folic acid taken before conception, gestational age <10 
weeks at first antenatal contact, and not taking potentially harmful medications (Angiotensin 




In this national observational study, the sample size was governed by the incidence of 
pregnancies complicated by diabetes, so no formal power calculations were performed. The 
statistical analysis plan was agreed by the NPID advisory group. The hypothesis of interest was 
to determine the contribution of modifiable risk factors (HbA1c levels, BMI, pre-pregancy care, 
maternity clinic attended) to pregnancy outcomes after adjustment for confounding maternal 
characteristics (age, ethnicity, deprivation, diabetes type and duration, co-morbidities). We also 
explored the impact of clinic-to-clinic variations on glycaemic attainment and obstetric 
complications (preterm delivery, large birthweight) to identify whether there were any 
particularly effective maternity clinics. 
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When examining obstetric complications and adverse pregnancy outcomes (congenital 
anomaly, stillbirth, neonatal death), we used all data collected during the 5-year study period. 
For perinatal deaths, the regression model included diabetes type and duration, maternal age, 
BMI, deprivation quintile, first trimester HbA1c, folic acid, potentially harmful medications 
and third trimester HbA1c. For congenital anomaly, third trimester HbA1c was omitted. We ran 
separate models for type 1 and type 2 diabetes where applicable and only factors which were 
statistically significant in univariate analyses were retained in multivariate analyses. Because 
neonatal deaths may have been underreported in 2014, a post hoc analysis compared neonatal 
death rates in type 1 and type 2 diabetes during 2015-2018.  
 
For exploring the impact of maternity clinic attended, we used data collected during 2017-2018 
when audit participation was stable (166 clinics in 2017, 164 clinics in 2018). This ensured as 
homogenous a group as possible. For data protection of potentially sensitive information in the 
clinic-to-clinic regression models, we excluded clinics with fewer than five outcomes.  
 
Variables which were not normally distributed are given as median (interquartile range, IQR) 
while normally distributed variables are given as mean (SD). Univariate analyses comparing 
the proportions between groups were performed using z-tests and t-tests for comparing 
continuous variables. We used SAS EG v7.1 for analyses and Poisson distribution to obtain 





The number of National Health Services (NHS) maternity clinics who participated across the 
five years ranged from 150 to 172. There was some variation in participating clinics with 13 
clinics submitting data for the first time in 2017-18, and an increase in pregnancies reported 
during 2017 and 2018, both before and after requirement for written consent was removed in 
England. Data on 17,375 diabetes pregnancies, including 700 congenital anomalies, 345 
perinatal deaths (195 stillbirths, 150 neonatal deaths) in 15,290 pregnant women with diabetes 
are included (Table 1). 
 
Maternal characteristics  
Half of the pregnancies (n=8685) were in women with type 2 diabetes (Table 2).  As expected, 
women with pregnancies complicated by type 2 diabetes were older, and had a shorter duration 
of diabetes. Compared to women with type 1 diabetes, they were more likely to live in areas 
of deprivation, be of Asian or Black ethnicity and be overweight or obese. Among women with 
type 1 diabetes, about 20% more pregnancies than expected (according to general population 
conception statistics) occurred in women with greater deprivation. The socioeconomic gradient 
in conceptions was particularly pronounced in women with type 2 diabetes, with more than 
40% living in the most deprived and less than 6% in the least deprived quintile.  
 
Pregnant women with type 2 diabetes presented for antenatal care approximately two weeks 
later than women with type 1 diabetes, and had higher rates of treatment with antihypertensive 
and lipid-lowering medications and lower rates of 5mg preconception folic acid. They also had 
lower HbA1c and were more likely than women with type 1 diabetes to achieve the NICE 
glycaemic target of HbA1c <48mmol/mol (6.5%). Almost two thirds of women with type 2 
diabetes (64.9%) were taking metformin in early pregnancy (ESM 2). There were no changes 
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in folic acid use but there was a reduction in potentially harmful medication usage in women 
with type 2 diabetes over the five-year study period (ESM 3). Insulin pump therapy was used 
by 1890 (22.4%) women with type 1 diabetes, increasing from 19.3% in 2014 to 24.8% in 2018 
(ESM 4). There were no changes in maternal glycaemia over the five-year study period (ESM 
5).  
 
Obstetric and neonatal complications 
Rates of preterm births, large for gestational age babies and neonatal care admissions were all 
higher in type 1 diabetes, while rates of small for gestational age babies (5.4% type 1, 14.1% 
type 2; p<0.001) were higher in type 2 diabetes. In type 1 diabetes, the rates of preterm births 
and large for gestational age babies also increased over the five-year study period (ESM 6). 
 
Adverse pregnancy outcomes 
Women with pregnancies complicated by type 2 diabetes had a comparable stillbirth rate 
(10.4/1000 type 1, 13.5/1000 type 2; p=0.072) and a significantly higher neonatal death rate 
(7.4/1000 type 1, 11.2/1000 type 2; p=0.013) (Table 1, Figure 1). The increased neonatal death 
rate in type 2 diabetes persisted after excluding data from 2014; (8.1/1000 type 1, 11.7/1000 
type 2 in 2015-2018; p=0.036). There were 700 congenital anomalies (ESM 7) with no 
difference in prevalence (44.8/1000 type 1, 40.5/1000 type 2; p=0.175) between type 1 and 
type 2 diabetes. Women with type 2 diabetes had higher rates of perinatal death across all third 
trimester HbA1c categories below 86mmol/mol (Figure 2); HbA1c <43mmol/mol (0.6% type 
1, 0.9% type 2), HbA1c 44-52mmol/mol (1.2% type 1, 2.7% type 2), HbA1c 53-63mmol/mol 
(1.7% type 1, 4.0% type 2), HbA1c 64-74mmol/mol (1.7% type 1, 4.9% type 2), HbA1c 75-
85mmol/mol (8.3% type 1, 10.0% type 2). 
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Among the entire cohort, independent risk factors for perinatal death were third trimester 
HbA1c  48mmol/mol (OR 3.06, 95% CI 2.16-4.33), living in the highest deprivation quintile 
(OR 2.29 95% CI 1.16-4.52) and having type 2 diabetes (OR 1.65 95% CI 1.18-2.31) (ESM 
8). When examined according to type of diabetes, only third trimester HbA1c  48mmol/mol 
(6.5%) remained significantly associated with perinatal death in both type 1 (OR 2.47 95% CI 
1.49-4.08) and type 2 diabetes (OR 3.93 95% CI 2.51-6.16).  
 
For congenital anomaly, only first trimester HbA1c  48mmol/mol (OR 1.70 95% CI 1.35-2.14) 
and not taking 5mg preconception folic acid (OR 1.31 95% CI 1.08-1.58) were significant 
independent risk factors among the entire cohort. When examined by type of diabetes, an above 
target HbA1c remained significantly associated with congenital anomaly in type 1 (OR 1.79, 
95% CI 1.2-2.7) and type 2 diabetes (OR 1.64, 95% CI 1.23-2.21) with not taking folic acid 
(OR 1.30, 95% CI 1.02-1.65) also significant in type 1 diabetes.  
 
Variation in HbA1c   
Variation in target HbA1c attainment in early pregnancy was more dependent on maternal 
characteristics than maternity clinic attended. Specifically, after adjustment for maternal age, 
ethnicity, deprivation, BMI, type and duration of diabetes, we found minimal variation between 
clinics, with most falling within the expected distribution (Figure 3). In type 1 diabetes, women 
with target HbA1c were older (35-44yrs) and had shorter diabetes duration (Figure 4, ESM 9). 
Younger women (<24yrs), with higher deprivation, longer diabetes duration, and higher BMI 
were less likely to achieve target HbA1c. In women with type 2 diabetes, longer diabetes 




Likewise, HbA1c in late pregnancy was more strongly associated with maternal characteristics 
than maternity clinic attended (Figure 3). First trimester HbA1c was the most important 
predictor for third trimester HbA1c in type 1 and type 2 diabetes, with diabetes duration also 
contributing. There was a direct association between higher maternal BMI and above target 
third trimester HbA1c in type 1 diabetes (ESM 10).  
 
Variation in obstetric complications 
We found some differences across clinics in the rates of preterm births, with six clinics falling 
two standard deviations above the expected average rates (Figure 5). Factors associated with 
preterm birth in type 1 diabetes were younger maternal age (<24yrs), deprivation, longer 
diabetes duration and higher HbA1c (ESM 11). Higher first and third trimester HbA1c and 
longer diabetes duration were also associated with preterm birth in type 2 diabetes. Black and 
Asian women were more likely to have term births.  
 
Variation in large for gestational age birthweight was strongly associated with maternal 
characteristics with no evidence for substantial variation between clinics (Figure 5). Factors 
associated with having a large birthweight baby in type 1 diabetes were not taking potentially 
harmful medications (reflecting less maternal comorbidity) and higher first and third trimester 
HbA1c (ESM 12). Being older (35-44 years) and presenting for antenatal care after 10 weeks 
gestation were associated with reduced risk for large birthweight. An above target HbA1c, 
especially during the third trimester, was associated with large birthweight in type 2 diabetes, 




In pregnant women with type 2 diabetes, we found higher than expected rates of perinatal 
death. Third trimester HbA1c was the dominant risk factor, both in women with type 1 and type 
2 diabetes. In pregnant women with type 1 diabetes, above target HbA1c was common and 
increased with maternal obesity, while rates of preterm births and large birthweight babies were 
elevated and rising. We did not identify any clinics that were significantly more effective in 
achieving optimal glycaemic or neonatal birthweight outcomes.  
To our knowledge, this is the largest, most detailed contemporary dataset in pregnant women 
with diabetes. It included 200 perinatal deaths in type 2 diabetes (110 stillbirths, 90 neonatal 
deaths), and 145 (85 stillbirths, 60 neonatal deaths) in type 1 diabetes. Previous studies 
included fewer pregnant women, especially those with type 2 diabetes (6). A Scottish study 
recently reported pre-pregnancy HbA1c and BMI as key risk factors associated with stillbirth 
in type 2 diabetes. We found that after adjusting for these and other risk factors, an above target 
third trimester HbA1c was associated with a four-times increased risk of perinatal death in type 
2 diabetes. We also found that across all third trimester HbA1c categories, pregnant women 
with type 2 diabetes had higher rates of perinatal death compared to women with type 1 
diabetes. 
 
Studies in general maternity populations have demonstrated that stillbirth rates are increased 
at birthweight extremes, and that growth-restricted pregnancies have the highest risk (15-17). 
Scottish data confirmed these findings in diabetes pregnancies, describing a six-times increased 
risk of stillbirth in small and a two-times increased risk in large birthweight babies (18). The 
higher rates of small for gestational age babies in type 2 diabetes likely contributes to the higher 
odds of perinatal death in our cohort.  
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Large birthweight remains the commonest complication of pregnancy in type 1 and type 2 
diabetes. Consistent with Scottish data, where the large birthweight rate increased in type 1 
diabetes during 1998-2013, we also found a temporal increase over the five years from 2014-
2018 (2). The reasons for this are unclear. Although we confirm the known association with 
higher HbA1c, we found no association with obesity, possibly because we used customised 
growth centiles, and because of the interaction between higher BMI and glycaemia. 
Interestingly, we found no glycaemic deterioration as reported in other cohorts (19). Women 
not taking antihypertensive or lipid lowering treatments had an increased risk, suggesting that 
in addition to glycaemia, maternal co-morbidities which influence placental vascular function 
are important. We also found that no maternity clinics were significantly more effective for 
achieving optimal birthweight outcomes.  
 
Potentially modifiable risk factors 
Surprisingly few women with type 2 diabetes were taking insulin (18%) or 5mg folic acid 
(22%) in early pregnancy, suggesting that despite two decades of adverse pregnancy outcomes, 
type 2 diabetes is still considered a less serious condition. Almost two thirds (65%) of women 
with type 2 diabetes were taking metformin, demonstrating healthcare engagement but missed 
opportunities for improving pregnancy preparation. Previous studies have confirmed that pre-
pregnancy programmes are effective, but that fewer women with type 2 diabetes attend (20, 
21). Qualitative studies suggest that unhelpful beliefs about age, obesity and fertility need to 
be addressed for more effective implementation of pre-pregnancy care in women with type 2 
diabetes (22).  
 
Raised HbA1c was associated with higher rates of adverse outcome in both type 1 and type 2 
diabetes pregnancies. A third of women with type 1 diabetes were overweight, with almost a 
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quarter obese, which was adversely associated with glycaemic attainment. Women with type 1 
diabetes may require additional dietary and psychosocial support to optimise their weight in 
order to achieve the pregnancy glucose targets. Younger women with type 1 diabetes (aged 15-
24 years) were most at risk for entering pregnancy with higher HbA1c, suggesting unplanned 
pregnancies and implying that greater attention to contraception provision across paediatric 
and young adult diabetes services may yield benefit.  
 
In type 2 diabetes, the modifiable risk factors for higher HbA1c included duration of diabetes 
and maternal obesity, both of which can be mitigated by intensive dietary interventions (23, 
24). Many women with type 2 diabetes (between one third and half) will have experienced 
previous pregnancies complicated by gestational diabetes (25). There is an urgent need to 
accelerate diabetes prevention programmes that proactively engage women with gestational 
diabetes (26).  
 
The lack of clinic-to-clinic variation in glycaemic attainment suggests that changes to maternity 
diabetes care are required in order for all clinics to achieve optimal glycaemia across a broader 
range of women. Interventions such as the introduction of continuous glucose monitoring may 
improve antenatal glucose levels and neonatal health outcomes in type 1 diabetes (27). Many 
maternal characteristics (younger age, higher deprivation, longer diabetes duration) associated 
with higher HbA1c are not modifiable, so targeting dietary, educational and technological 
resources, such as automated insulin delivery, towards women with the highest risk profiles 
may be required (28). Women with type 2 diabetes need culturally appropriate pre-pregnancy 
and antenatal care. In addition, input from multidisciplinary obesity services as well as tighter 
glucose targets, potentially achievable using continuous glucose monitoring systems, may be 
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applicable (29). Further evaluation of the impact of metformin on small for gestational age 
birthweight and stillbirth is needed (30). 
A major strength is the identification of a detailed, national cohort of pregnant women with 
diabetes with high case ascertainment across UK maternity units. The large sample which 
included 345 perinatal deaths, yielded robust estimates for serious adverse pregnancy 
outcomes. In addition, data from >150 maternity clinics allowed a depth of analysis not 
previously possible, including the development of national average rates for glycaemic 
attainment and obstetric complications. Our dataset variable list is limited to key pregnancy 
outcomes and lacks data on diabetes complications. We acknowledge data quality issues of 
‘real-world’ clinical data especially for diabetes diagnosis and medication usage, however this 
affects ony a small number (1.3%) of pregnancies and is unlikely to impact our results. Also, 
we cannot determine the impact of the continued  requirement for consent in Wales, but do not 
expect this to impact our findings. Other limitations include data missingness with fewer 
HbA1c measurements in type 2 diabetes pregnancies (>80% type 1, 72% type 2), no 




Our findings have implications for research, healthcare policy and clinical practice. Our results 
can serve as a reference point from which to judge the effectiveness of future interventions to 
optimise pregnancy outcomes in type 1 and type 2 diabetes. They highlight ongoing, 
unchanged adverse pregnancy outcomes in type 1 diabetes and increased perinatal deaths in 
type 2 diabetes. Improving pregnancy outcomes is a shared challenge which requires better 
diabetes healthcare system integration across primary care, paediatric and young adult clinics 
as well as adult diabetes, obesity and maternity services.  
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Research in Context 
Evidence before this study 
We searched PubMed for articles published before July 30, 2020, without restriction on 
language or start date.  We included the search terms (“Diabetes Mellitus” OR “Diabetes”), 
AND “pregnancy”, OR “pregnancy in diabetics”, AND “congenital anomaly”, AND 
(“perinatal death”) AND (“stillbirth”) AND (“neonatal death”). Previous studies were 
conducted 15-20 years ago and included far fewer pregnant women, especially those with 
type 2 diabetes. The UK Confidential Enquiry into Maternal and Child Health (CEMACH) 
conducted during 2002-03 documented a threefold increase in perinatal mortality and a 
twofold increase in the congenital anomaly rate in women with diabetes. They described 25 
perinatal deaths (19 stillbirths, 6 neonatal deaths) in 652 women with type 2 diabetes, with 
comparable rates in women with type 1 and type 2 diabetes. They noted high levels of ethnic 
diversity, obesity, deprivation and poor preparation for pregnancy in women with type 2 
diabetes. A Scottish study conducted during 1998-2016 described 37 stillbirths in 1614 
women with type 2 diabetes, again highlighting the importance of pre-pregnancy care.  
 
Added value of this study 
Our national cohort of 17,375 pregnancies described the glycaemic status and pregnancy 
outcomes in 15,290 women, half of whom had type 2 diabetes. In pregnant women with type 
2 diabetes, we found higher than expected rates of perinatal death. Third trimester 
HbA1c>48mmol/mol (6.5%) was associated with a four-times increased risk for perinatal 
death.  Across all third trimester HbA1c categories, pregnant women with type 2 diabetes had 
higher rates of perinatal death compared to women with type 1 diabetes suggesting that more 
vigilant attention to antenatal glucose levels is needed in type 2 diabetes. In pregnant women 
with type 1 diabetes, HbA1c levels above 48mmol/mol (6.5%) increased with maternal 
obesity, while rates of preterm births and large birthweight babies were elevated and rising. 
Glycaemic attainment was associated with maternal obesity as well as non-modifiable 
characteristics (maternal age, deprivation, diabetes duration) but not by maternity clinic 
attended. 
 
Implications of all the available evidence 
Our data highlight persistent adverse pregnancy outcomes in type 1 and type 2 diabetes and 
higher perinatal deaths in type 2 diabetes. They reinforce the critical importance of maternal 
glycaemia as the key modifiable risk factor and the negative impact of obesity in women with 
both types of diabetes. Improving pregnancy outcomes is a shared challenge which likely 
requires better diabetes healthcare system integration across primary care, paediatric and 
young adult clinics as well as adult diabetes, obesity and maternity services plus new systems 
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Table 1: Numbers of clinics, women, pregnancies and babies during 2014-2018 
 2014 2015 2016 2017 2018 
Clinicsa 150 155 172 166 164 
Women  2537 3036 3297 3840 4390 
Pregnanciesb  2553 3044 3304 3855 4400 
Total pregnancy outcomesc 2584 3086 3356 3910 4465 
Pregnancies ongoing after 24 
weeks 
2387 2866 3091 3545 4030 
Live Births after 24 weeks 2390 2868 3108 3550 4035 
Stillbirthsd 28 37 35 40 55 
Stillbirth rate per 1,000 live and 











Babies born after 24 weeks 2390 2903 3140 3590 4090 
Neonatal deathse 14 30 31 35 40 
Neonatal death rate per 1,000 











Total registered births 2433 2908 3145 3600 4090 
aThere are a range of maternity clinics submitting data; for example in 2018 the mean number 
of pregnancies per clinic was 27 but there were 20 clinics with fewer than 10 pregnancies and 
4 clinics with more than 80 pregnancies.  
bThere was an increase in pregnancies reported during 2017 and 2018, both before and after 
requirement for written consent was removed in England. Details of the data quality 
procedures and the number of participating clinics are available 
https://files.digital.nhs.uk/79/4B7BB9/National%20Pregnancy%20in%20Diabetes%20Audit
%20Report%202018%20Data%20Quality%20Statement.pdf 
cTotal pregnancy outcomes include pregnancy loss before 24 weeks, pregnancy terminations 
livebirths and stillbirths. Each fetus/baby is counted so a twin pregnancy is counted as two 
pregnancy outcomes 
dAlthough there was an increase in the number of stillbirths from 2014-2018 there was 
no significant change in the overall stillbirth rate 
eWe believe that neonatal deaths were underrepresented in type 1 diabetes in 2014. 
When the 2014 data are excluded, there was no significant change in the overall 
neonatal death rate from 2015-2018 
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Table 2: Maternal and neonatal characteristics by diabetes type  
 Type 1 diabetesa 
n=8690 (50%) 
Type 2 diabetes 
n=8685 (50%) 
p value 
Age at delivery (years) 30 (22-37) 34 (27-41)  
Duration of diabetes (years) 13.0 (3-25) 3.0 (0-10)  
Weight at booking (kg) 70 (56.3-93.0) 85.6 (62.0-117.0)  
BMI at booking (kg/m2) 25.9 (21.3-33.8) 32.5 (24.8-43.0)  
BMI category n=8680 n=8680  
  18.5–24.9 3640 (41.9%) 915 (10.5%) <0.001 
  25–29.9 3060 (35.3%) 2125 (24.5%) <0.001 
  ≥30 1975 (22.8%) 5640 (65.0%) <0.001 
Ethnicity b n=8645 n=8360  
  White  7370 (85.3%) 3610 (43.2%) <0.001 
  Asian 335 (3.9%) 2980 (35.6%) <0.001 
  Black 185 (2.1%) 805 (9.6%) <0.001 
  Mixed 110 (1.3%) 205 (2.5%) <0.001 
         Other 140 (1.6%) 240 (2.9%) <0.001 
  Not stated/unknown 510 (5.9%) 520 (6.2%) 0.381 
Deprivation quintile n=8220 n=7780  
  1: least deprived 1285 (15.6%) 445 (5.7%) <0.001 
  2 1465 (17.8%) 740 (9.5%) <0.001 
  3 1670 (20.3%) 1315 (16.9%) <0.001 
  4 1790 (21.8%) 2055 (26.4%) <0.001 
  5: most deprived 2010 (24.5%) 3225 (41.5%) <0.001 
Treated Hypertension n=7460  n=7825   
 275 (3.7%) 805 (10.3%) <0.001 
Markers of pregnancy preparation n=8685 n=8680  
5mg folic acid preconception 3830 (44.1%) 1930 (22.3%) <0.001 
ACE inhibitor/ARB 105 (1.2%) 355 (4.1%) <0.001 
Statin  130 (1.5%) 460 (5.3%) <0.001 
Gestation at first contact (weeks) 7 (4-12) 9 (5-15)  
Maternal Glycemia n=7135 n=6265  
Early HbA1c (mmol/mol) 60.0 (44.0–88.0) 51.5 (39.0–83.0)  
  HbA1c <48 mmol/mol (6.5%) 1135 (15.9%) 2285 (36.5%) <0.001 
Late pregnancy HbA1c n=6515 n=5885  
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  HbA1c (mmol/mol) 50 (38–66) 42 (33–56)  
  HbA1c <48 mmol/mol (6.5%) 2715 (41.7%) 4335 (73.7%) <0.001 
Obstetric outcomes n=7825 n=7815  
  Gestational age at delivery (wks) 37 (34-38) 38 (35-39)  
  Preterm delivery <37+0 weeks 3325 (42.5%) 1825 (23.4%) <0.001 
  Preterm delivery <34+0 weeks  720 (9.2%) 395 (5.1%) <0.001 
Infant birthweight percentiles n=7845 n=7885  
  LGA >90th percentile  4095 (52.2%) 2065 (26.2%) <0.001 
  SGA >10th percentile 420 (5.4%) 1115 (14.1%) <0.001 
Neonatal care admission n=8060 n=8035  
  Special care unit 2470 (30.6%) 1440 (17.9%) <0.001 
  Intensive care unit 1025 (12.7%) 630 (7.8%) <0.001 
Adverse pregnancy outcome n=8150 n=8150  
  Congenital anomalyc 365 (44.8/1000) 330 (40.5/1000) 0.175 
  Stillbirth  85 (10.4/1000) 110 (13.5/1000) 0.072 
 n=8065 n=8035  
  Neonatal death 60 (7.4/1000) 90 (11.2/1000) 0.013 
Data are presented as n (%), or n (n per 1000 births) and median (10-90th percentile) as 
appropriate 
aType of diabetes was clinically defined by local diabetes maternity teams. Some data quality 
issues were noted with 1.3% of women with type 1 diabetes not taking insulin. Details of the 
data quality procedures and the number of participating clinics are available 
https://files.digital.nhs.uk/79/4B7BB9/National%20Pregnancy%20in%20Diabetes%20Audit
%20Report%202018%20Data%20Quality%20Statement.pdf 
bEthnicity data are obtained by data linkage with the National Diabetes Audit based on self-
identified ethnicity as recorded by GP practice. Women of Asian or Black ethnicity 
comprised 5% of type 1 diabetes pregnancies in deprivation quintile 1 (least deprived) and 
14% of those in quintile 5 (most deprived); by contrast the proportions of women of Asian or 
Black ethnicity with type 2 diabetes pregnancies were 38% (least deprived) and 58% most 
deprived). 
cIncludes major and minor congenital anomalies identified based on the ICD10 codes 
prior to hospital discharge.  
d These data are applicable for singleton pregnancies. Birthweight was adjusted for 
maternal BMI, ethnicity, neonatal sex and gestational age for singleton pregnancies 
using the Gestation Related Optimal Weight (GROW) centile tool v8 0.4 (UK) 2019 
Gestation Network (12). Maternal ethnicity categories included European (British, 
Irish, North, South, East & West European), African (North, East, Central, West & 
South African), Middle Eastern (Iraq, Israel, Jordan, Lebanon, Saudi Arabia, Syria, 
Turkey), Bangladeshi, Indian (India & Sri Lanka), Pakistani, Chinese (China, Hong 
Kong, Taiwan), Far East Asia (Japan, Korea, Mongolia), South East Asia (Brunei, 
Cambodia, Indonesia, Malaysia, Myanmar, Philippines, Thailand), Caribbean 
(Barbados, Cuba, Jamaica, Puerto Rico), Mixed African-European, Mixed Asian-
European, Mixed Caribbean-European and other (Australasia, Americas, Asia-other). 
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Figure 1: Perinatal death rates in type 1 and type 2 diabetes  
Top panel: Stillbirth rate per 1,000 live and stillbirths. The stillbirth rates in type 1 diabetes 
are unchanged during 2014-2018 but stillbirth rates in type 2 diabetes appear higher since 
2016. 
Bottom panel: Neonatal death rate per 1,000 livebirths. We believe that neonatal deaths may 
have been underrepresented in type 1 diabetes in 2014. 
 
Figure 2: Adverse pregnancy outcome and maternal HbA1c level in pregnancies 
complicated by type 1 and type 2 diabetes  
Top panel: Rates of congenital anomaly or perinatal death and early pregnancy HbA1c 
Bottom panel: Rates of perinatal death (stillbirth and neonatal death) and late pregnancy 
HbA1c 
The HbA1c categories are <43mmol/mol (<6.1%), HbA1c 44-52mmol/mol (6.2-6.9%), 
HbA1c 53-63mmol/mol (7.0%-7.9%), HbA1c 64-74mmol/mol (8.0%-8.9%), HbA1c 75-
85mmol/mol (9.0-9.9%), HbA1c ≥86mmol/mol (10%). 
 
Figure 3: Variation between clinics in glycaemic attainment 
Top panel: The proportion of women with target HbA1c in early pregnancy. The funnel plot 
shows the standardised ratio for first trimester HbA1c <48mmol/mol (6.5%) during 2017-
2018 adjusting for maternal age, diabetes type, duration of diabetes, ethnicity, deprivation 
and BMI at the first antenatal appointment. Services with an expected value of 5 or fewer 
have been excluded. Model c statistic = 0.70 
 
Bottom panel: The proportion of women with target HbA1c in late pregnancy. The funnel 
plot shows the standardised ratio for third trimester HbA1c <48mmol/mol (6.5%) during 
2017-2018 adjusting for maternal age, diabetes type, duration of diabetes, ethnicity, 
deprivation, HbA1c and BMI at the first antenatal appointment. Services with an expected 
value of 5 or fewer have been excluded. Model c statistic = 0.82 
 
Figure 4: Impact of maternal characteristics on glycaemic attainment 
Odds ratios of factors associated with achieving a first trimester HbA1c of less than 48 
mmol/mol (6.5%). Separate multivariate analyses were run for type 1 and type 2 diabetes  
 
Figure 5: Variation between clinics in rates of obstetric complications 
Top panel: The funnel plot shows the standardised ratio for the rate of preterm births during 
2017-2018 adjusting for type and duration of diabetes, maternal age, deprivation, ethnicity, 
gestational age at first contact, HbA1c in early and late pregnancy, congenital anomaly and 
LGA. There are six clinics whose standardised ratio falls outside 2SD. Services with an 
expected value of 5 or fewer have been excluded. Model c statistic = 0.71.  
 
Bottom panel: The funnel plot shows the standardised ratio for the rate of LGA babies with 
birthweight  90th centile during 2017-2018 adjusting for maternal age, diabetes type, 
duration of diabetes, first and third trimester HbA1c, medications at conception and 
gestational age at first contact. Maternal BMI was not retained in the regression model as it 
did not add statistical power.  Services with an expected value of 5 or fewer have been 
excluded. Model c statistic = 0.71 
 
 
